A Phase 2 interventional study of MORF-057 and Placebo in Inflammatory Bowel Diseases and Colitis, Ulcerative, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company). Completed at 102 sites in 21 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Colitis, Ulcerative by Eli Lilly and Company — 5 open to participants now, 7 under way, 3 of them phase 3. Colitis, Ulcerative · Eli Lilly and Company.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, this one is the 6th largest by enrollment, is one of 2 that started in 2022, is one of 8 in phase 2, and was the 9th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 16 studies in Colitis, Ulcerative by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in United States, Argentina, Brazil and 25 more countries
Ages 18–80
Eli Lilly and Company · Sites in United States, Austria, Brazil and 14 more countries
Ages 18–80
Eli Lilly and Company · Sites in United States, Austria, Belgium and 20 more countries
Ages 18–70
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 280 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 211 across the 16 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), one of the names counted as Eli Lilly and Company. Under that name alone:
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
2 of the studies in Colitis, Ulcerative by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186101Eli Lilly and CompanyLY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: | 2027-05 |
| NCT07483073Eli Lilly and CompanyA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three active dose regimens of MORF-057 plus a placebo regimen in study participants with moderately to severely active UC. After completion of the 12-week Induction Period, participants may be switched to a different active MORF-057 regimen during the Maintenance Period. Those randomized into the placebo group in the Induction Period will be switched to receive an active MORF-057 regimen during the Maintenance Period.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
This study's enrollment of 280 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Browse Colitis, Ulcerative studies →Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
First submitted before Morphic Therapeutic, Inc. became part of Eli Lilly and Company.
Compared within Colitis, Ulcerative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a 200 milligram (mg) oral dose of MORF-057 twice daily (BID) for 12 weeks.
Drug: MORF-057
Participants received a 100 mg oral dose of MORF-057 twice daily for 12 weeks.
Drug: MORF-057
Participants received a 100 mg oral dose of MORF-057 once daily in the morning (QD-M) for 12 weeks.
Drug: MORF-057
Participants received an oral dose of matching placebo for 12 weeks.
Drug: Placebo
MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
Also known as: LY4268989
Matching placebo (identical appearance to MORF-057) administered orally.
Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS)
* The mMCS is a scoring system for assessment of ulcerative colitis activity and is a composite of Endoscopic subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration)), Stool Frequency subscore (range: 0=Normal number of stools to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The mMCS total score ranges from 0 to 9, with higher scores indicating more severe disease. * Clinical remission per mMCS is defined as rectal bleeding subscore of 0; a stool frequency subscore of \< or =1; and an endoscopy subscore of \< or =1 without friability.
Time frame: Week 12
Percentage of Participants in Clinical Response as Determined Using the Modified Mayo Clinic Score (mMCS)
* The mMCS is a scoring system for assessment of ulcerative colitis activity and is a composite of Endoscopic subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration)), Stool Frequency subscore (range: 0=Normal number of stools to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The mMCS total score ranges from 0 to 9, with higher scores indicating more severe disease. * Clinical response per mMCS is defined as decrease from baseline in the mMCS score \> or =2 points and \> or =30% from baseline, plus a decrease in rectal bleeding subscore \> or =1 or an absolute rectal bleeding subscore \< or =1.
Time frame: Week 12
| Milestone | MORF-057 200 mg BID | MORF-057 100 mg BID | MORF-057 100 mg QD-M | Placebo |
|---|---|---|---|---|
| Started | 69 | 71 | 70 | 70 |
| Safety analysis population | 70 | 71 | 70 | 69 |
| Completed | 65 | 68 | 67 | 65 |
| Not completed | 4 | 3 | 3 | 5 |
| Withdrew: Adverse event | 1 | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 2 | 1 |
* The mMCS is a scoring system for assessment of ulcerative colitis activity and is a composite of Endoscopic subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration)), Stool Frequency subscore (range: 0=Normal number of stools to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The mMCS total score ranges from 0 to 9, with higher scores indicating more severe disease. * Clinical remission per mMCS is defined as rectal bleeding subscore of 0; a stool frequency subscore of \< or =1; and an endoscopy subscore of \< or =1 without friability.
| percentage of participants | MORF-057 200 mg BID | MORF-057 100 mg BID | MORF-057 100 mg QD-M | Placebo |
|---|---|---|---|---|
| Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) | 31.9 | 23.9 | 17.1 | 24.3 |
* The mMCS is a scoring system for assessment of ulcerative colitis activity and is a composite of Endoscopic subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration)), Stool Frequency subscore (range: 0=Normal number of stools to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The mMCS total score ranges from 0 to 9, with higher scores indicating more severe disease. * Clinical response per mMCS is defined as decrease from baseline in the mMCS score \> or =2 points and \> or =30% from baseline, plus a decrease in rectal bleeding subscore \> or =1 or an absolute rectal bleeding subscore \< or =1.
| percentage of participants | MORF-057 200 mg BID | MORF-057 100 mg BID | MORF-057 100 mg QD-M | Placebo |
|---|---|---|---|---|
| Percentage of Participants in Clinical Response as Determined Using the Modified Mayo Clinic Score (mMCS) | 62.3 | 53.5 | 57.1 | 54.3 |
Collected over Baseline to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MORF-057 200 mg BID | 0/70 (0%) | 1/70 (1.4%) | 9/70 (12.9%) |
| MORF-057 100 mg BID | 0/71 (0%) | 3/71 (4.2%) | 8/71 (11.3%) |
| MORF-057 100 mg QD-M | 0/70 (0%) | 0/70 (0%) | 5/70 (7.1%) |
| Placebo | 0/69 (0%) | 1/69 (1.4%) | 10/69 (14.5%) |
| Event | MORF-057 200 mg BID | MORF-057 100 mg BID | MORF-057 100 mg QD-M | Placebo |
|---|---|---|---|---|
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/70 | 0/71 | 0/70 | 1/69 |
| Colitis ulcerativeGastrointestinal disorders | 1/70 | 1/71 | 0/70 | 0/69 |
| Aspartate aminotransferase increasedInvestigations | 0/70 | 1/71 | 0/70 | 0/69 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/70 | 1/71 | 0/70 | 0/69 |
| Event | MORF-057 200 mg BID | MORF-057 100 mg BID | MORF-057 100 mg QD-M | Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 5/70 | 4/71 | 2/70 | 2/69 |
| AnaemiaBlood and lymphatic system disorders | 2/70 | 2/71 | 3/70 | 4/69 |
| NasopharyngitisInfections and infestations | 3/70 | 3/71 | 0/70 | 4/69 |
All randomized participants.
| Age, Continuous(years) | MORF-057 200 mg BID | MORF-057 100 mg BID | MORF-057 100 mg QD-M | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 41.0 ± 17.14 | 41.8 ± 14.35 | 38.9 ± 13.57 | 39.1 ± 13 | 40.2 ± 14.57 |
| Sex: Female, Male(Participants) | MORF-057 200 mg BID | MORF-057 100 mg BID | MORF-057 100 mg QD-M | Placebo | Total |
|---|---|---|---|---|---|
| Female | 28 | 32 | 31 | 34 | 125 |
| Male | 41 | 39 | 39 | 36 | 155 |
| Ethnicity (NIH/OMB)(Participants) | MORF-057 200 mg BID | MORF-057 100 mg BID | MORF-057 100 mg QD-M | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 1 | 2 | 6 |
| Not Hispanic or Latino | 66 | 70 | 69 | 68 | 273 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | MORF-057 200 mg BID | MORF-057 100 mg BID | MORF-057 100 mg QD-M | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 14 | 11 | 13 | 13 | 51 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 53 | 60 | 57 | 57 | 227 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 0 | 2 |
Showing the first 100 of 102 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2022 to primary completion in Nov 2024, 24 months.
Results were first posted in Dec 2025, 1 year after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 24 months is below that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 15, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MORF-057
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) →